Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. - Wikidata - awgldk - TriplyDB

Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q39754589

about

Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting Summary of the published Indian data on chronic myeloid leukemia Oral antineoplastic agents: how do we care about adherence?The role of observational studies in optimizing the clinical management of chronic myeloid leukemia Chronic Myeloid Leukemia in India.Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study.Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.A Systematic Review of Adherence to Oral Antineoplastic Therapies Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.Adherence to oral antineoplastic agents by cancer patients: definition and literature review.A review of economic impact of targeted oral anticancer medications.Insights on practice variations in the management of lymphoma and leukemia.Improving adherence to oral cancer therapy in clinical practice.Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.Facilitators and Barriers to Self-Management for Adolescents and Young Adults Following a Hematopoietic Stem Cell Transplant.Culture, Styles of Institutional Interactions, and Inequalities in Healthcare Experiences.Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.Why are patients with chronic myeloid leukaemia (non-)adherent?Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative Study Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.

P2860

Q26850736-BAB58FC7-5DAA-460D-8ABE-B8AB689AF628 Q27008389-3C6D6F72-C749-4A5D-92B8-52455037E8BD Q28075574-915EDCFA-EA2A-46B5-A63F-0E69E84B368E Q28082909-F6799B9F-5AE4-46DF-BB39-31E3A2C2D5DD Q28085149-2B78F89D-618D-4808-92E9-0151CD67F68A Q33859551-251A8322-2922-4A1C-9EA7-BAF274DB1B7C Q34445704-C039B7F0-1AB6-414F-836C-110F70C6BD08 Q35130028-9628FCD2-7F9C-4976-B8D7-7225B8D4F81E Q36355098-91C2807A-69FE-4190-A7B2-28F126405EC0 Q36364850-3630256A-AF5A-4A40-971A-A3874DBF9352 Q36673490-ADE418FD-74C3-4039-9177-113C231BAA99 Q37057014-A4A8B543-814B-48C4-ADB9-37D81054F618 Q37365606-33A2A499-CDF1-4CC4-87B0-2A7F1A14EBCE Q37517333-B377BC36-9B90-41F1-B9DD-F86D7BDF799B Q37618888-E704D6EB-932A-4BF3-AE46-8A1795E4CC44 Q37628623-9EF62177-8321-4CA0-84D7-4EE2E17A1793 Q37999726-DEB14D3F-9E3B-4FB2-A4AE-2A96E5958FA0 Q38109527-65502325-C21F-4082-B2B0-49F9A6DE3480 Q38147533-F855586C-86B8-4CF4-BE9D-7AF9E4D49A1F Q38174702-AABFB871-D807-4F35-9CB7-DE7B6A178BAB Q38177354-B674A56D-F4C4-4954-9DAF-06B15A1DCEA1 Q38216035-9407508C-F2E7-40A7-9B87-5971A49B2E7B Q38356369-8C6454D1-328C-478C-A3C6-F60D516C3802 Q38428850-12F79D8A-EA00-4D67-96B8-6BC65BD24D2C Q38635342-5AF71563-1DF9-4368-99B1-FEC4C79FDDB7 Q38702545-A5227B93-E3F1-4DEB-B485-978EA8C2C2B2 Q38725806-3074C45F-5893-4240-9966-9A3E1F484A98 Q38880261-609347DD-3D4B-439C-8B31-AA4258C0C31D Q38943877-4947969A-994E-4985-940A-218B3B9C299D Q39350678-61A41AB1-082B-44A2-94D1-91AE91D0E8A4 Q41601810-74AEB31D-6C6D-47BB-B7B6-0BB5A4FA74D5 Q42395994-7F1575B5-5D7C-4274-A977-88C355FB9B84 Q42511529-F5B39312-F6B0-4438-B3F9-2DE2DEC4DCE8 Q42672759-9ABDC319-4AF1-46EE-922F-0E3CB53EC9CF Q44278420-C2F30B5B-F23F-4533-9347-47D6279EACB9 Q45358123-9F81BE5C-CD0C-4C17-9D63-F6C55DC48C1F Q46130279-F93CCD54-19FA-4C4B-8D75-61D190653286 Q47912298-3906B752-51B1-4D73-BEE7-E37204FF97D7 Q49888044-90FC91B7-EB61-424E-8389-AAD1B0F4892F Q50996253-0F621643-EABA-4291-B9C1-3FDD9ACB5C28

P2860

Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q39754589

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.

@en

Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.

@nl

type

label

Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.

@en

Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.

@nl

prefLabel

Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.

@en

Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.

@nl

P1433

Q39754589-7E6D9448-D76C-472A-9B60-4B7BCFAAABB2

P1476

Q39754589-86C28C1F-F331-4FB4-A199-05E2C14C7437

P2093

Q39754589-31160BAE-FC21-48D4-A4C8-A0133C6BD184

Q39754589-8B300387-B738-4BE0-81CA-5E7BB009CA20

Q39754589-B0755F50-A11E-4CC1-8C23-53D3D326EB19

Q39754589-D951CAD1-A8AB-4A4A-BF32-82D3F4B519D0

Q39754589-DDF7D1CD-F1A2-405C-A80E-EB4FBF992F3C

Q39754589-ED8A79B6-0BCC-4745-8FB3-6AD81684F931

P2860

Q39754589-0652D2EC-B0A9-41CE-AE5F-7507B856441B

Q39754589-49CD2EA3-4E07-44CE-B58A-18155A49A810

Q39754589-8A3FE112-F4C0-4F69-9357-0D58431F4138

Q39754589-8CBC1360-19CD-4286-91CF-C5967FC75A13

Q39754589-94494F6C-2ABB-4446-BA73-0D2C3F199592

Q39754589-AEF87D80-34FB-4DE1-A45D-18C45E3A95FC

Q39754589-B0880903-AC0F-4F6C-B0C0-43AD6534FE6C

Q39754589-D381C44C-4111-4FB4-AA26-3866ABD9F6B3

Q39754589-E85AA9F7-4EE4-426B-8C13-CD6978867F0E

Q39754589-F20A5E69-976A-49C9-AD5E-58844CD50FAF

P304

Q39754589-4AF23692-E476-4DFE-B40B-964DE2B332A1

P31

Q39754589-804F8645-A165-4B82-A522-200B858F304A

P356

Q39754589-D087123E-1BDA-4A25-A407-B628A2E205DE

P433

Q39754589-9D963DA3-5E75-4DB1-B65A-EA4D9DCDFA86

P478

Q39754589-7050E320-5D33-4028-8D60-D96BC5177189

P50

Q39754589-B1AD0E1B-487A-4BCF-934C-ECC11E2395C3

P577

Q39754589-4942D5BD-6E72-4D0A-8A76-26E819F17E8B

P698

Q39754589-513C5CAC-97B2-42E0-9A53-91B20D906244

P921

Q39754589-545B9F6E-A1A1-4D22-8F82-86112F8DC8B1

Q39754589-C682828F-38B2-4186-BF8B-97F07B0E14A2

P356

P1433

American Journal of Hematology

P1476

Nonadherence to imatinib adver ...... phase chronic myeloid leukemia

@en

P2093

Biswajit Dubashi

http://www.w3.org/2001/XMLSchema#string

Krishnarathinam Kannan

http://www.w3.org/2001/XMLSchema#string

Manjunath Nandennavar

http://www.w3.org/2001/XMLSchema#string

Rejiv Rajendranath

http://www.w3.org/2001/XMLSchema#string

Sanju Cyriac

http://www.w3.org/2001/XMLSchema#string

Tenali Gnana Sagar

http://www.w3.org/2001/XMLSchema#string

P2860

Adherence to therapy with oral antineoplastic agents

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Patient adherence and persistence with oral anticancer treatment.

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country.

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.

P304

471-474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.22019

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P50

Prasanth Ganesan

P577

2011-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21538468

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia